Mylan's War on Authorized Generics
This article was originally published in RPM Report
Executive Summary
Changes to the Medicaid law will put a crimp in the economics of "authorized" generic agreements. But Mylan won't be happy until Congress takes further action.
You may also be interested in...
FTC Study of Authorized Generics Gets Off the Ground: Now What?
A Federal Trade Commission analysis of the competitive impact of authorized generics has been in limbo for months. The agency recently received approval to go ahead with the controversial study from the executive branch. What should drug companies expect to receive in the mail?
The War on Generics - Part II
Teva says it isn't worried about the more aggressive pricing strategies used by brand companies to blunt blockbuster generic launches. What if the world's largest generic company is wrong? Part II of this two-part series looks at the future of the generic drug industry.
The War on Generics - Part I
Generic drug companies are riding high after the largest generic launch ever (Zocor) and arguably the cleverest (Plavix). But brand companies are fighting back, and they may succeed in taking away the biggest incentive fueling patent challenges.